Legacy Wealth Managment LLC ID Acquires New Holdings in Lixte Biotechnology Holdings, Inc. $NMAD

Legacy Wealth Managment LLC ID bought a new stake in Lixte Biotechnology Holdings, Inc. (NASDAQ:NMAD) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 600,669 shares of the company’s stock, valued at approximately $4,457,000. Lixte Biotechnology comprises about 2.0% of Legacy Wealth Managment LLC ID’s investment portfolio, making the stock its 13th largest holding. Legacy Wealth Managment LLC ID owned 3.73% of Lixte Biotechnology as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in NMAD. Axxcess Wealth Management LLC bought a new stake in shares of Lixte Biotechnology in the 4th quarter valued at about $54,000. XTX Topco Ltd bought a new position in shares of Lixte Biotechnology during the 4th quarter worth approximately $57,000. Geode Capital Management LLC raised its stake in shares of Lixte Biotechnology by 25.9% during the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after acquiring an additional 10,722 shares in the last quarter. Renaissance Technologies LLC lifted its position in Lixte Biotechnology by 47.0% during the fourth quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock valued at $422,000 after acquiring an additional 34,350 shares during the last quarter. Finally, Federation des caisses Desjardins du Quebec lifted its position in Lixte Biotechnology by 83.6% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after acquiring an additional 42,530 shares during the last quarter. 5.10% of the stock is currently owned by institutional investors.

Lixte Biotechnology Stock Performance

Shares of NMAD stock opened at $3.65 on Friday. Lixte Biotechnology Holdings, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $8.38. The firm has a market capitalization of $58.77 million, a price-to-earnings ratio of -3.65 and a beta of 1.30. The stock’s 50-day simple moving average is $6.56 and its 200-day simple moving average is $5.10.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Wall Street Zen downgraded shares of Lixte Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, August 22nd. Weiss Ratings downgraded Lixte Biotechnology from a “sell (e+)” rating to a “sell (e)” rating in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Lixte Biotechnology presently has an average rating of “Sell”.

Lixte Biotechnology Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.